Saturn V Capital Management
Latest statistics and disclosures from Saturn V Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are IRON, ASND, MLTX, CGON, PCVX, and represent 43.92% of Saturn V Capital Management's stock portfolio.
- Added to shares of these 10 stocks: XENE (+$13M), CTNM (+$7.3M), SNDX (+$6.4M), MRUS, AMLX, NAMS, MLTX, CGON, OCUL, CELC.
- Started 5 new stock positions in OCUL, NAMS, XENE, MBX, AMLX.
- Reduced shares in these 10 stocks: PHAT (-$16M), NMRA (-$5.7M), , CRNX, ITOS, COGT, ARGX, IRWD, AVBP, Longboard Pharmaceuticals In.
- Sold out of its positions in AVBP, BMRN, ITOS, Longboard Pharmaceuticals In, NMRA, PHAT.
- Saturn V Capital Management was a net buyer of stock by $9.4M.
- Saturn V Capital Management has $255M in assets under management (AUM), dropping by -8.72%.
- Central Index Key (CIK): 0001964437
Tip: Access up to 7 years of quarterly data
Positions held by Saturn V Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Saturn V Capital Management
Saturn V Capital Management holds 24 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Disc Medicine (IRON) | 12.6 | $32M | 509k | 63.40 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 10.7 | $27M | 199k | 137.67 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 7.3 | $19M | +15% | 346k | 54.15 |
|
| Cg Oncology (CGON) | 6.7 | $17M | +14% | 593k | 28.68 |
|
| Vaxcyte (PCVX) | 6.5 | $17M | 204k | 81.86 |
|
|
| Cytokinetics Com New (CYTK) | 6.4 | $16M | +5% | 348k | 47.04 |
|
| Cargo Therapeutics (CRGX) | 5.7 | $15M | 1.0M | 14.42 |
|
|
| Celcuity (CELC) | 5.5 | $14M | +12% | 1.1M | 13.09 |
|
| Syndax Pharmaceuticals (SNDX) | 5.1 | $13M | +96% | 989k | 13.22 |
|
| Xenon Pharmaceuticals (XENE) | 5.0 | $13M | NEW | 323k | 39.20 |
|
| Argenx Se Sponsored Adr (ARGX) | 4.8 | $12M | -10% | 20k | 615.00 |
|
| Cogent Biosciences (COGT) | 4.6 | $12M | -12% | 1.5M | 7.80 |
|
| Merus N V (MRUS) | 3.9 | $9.9M | +78% | 235k | 42.05 |
|
| Contineum Therapeutics Cl A (CTNM) | 3.3 | $8.4M | +641% | 573k | 14.65 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.9 | $4.8M | 653k | 7.32 |
|
|
| Kalvista Pharmaceuticals (KALV) | 1.8 | $4.7M | 557k | 8.47 |
|
|
| Inozyme Pharma (INZY) | 1.5 | $3.8M | 1.4M | 2.77 |
|
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 1.4 | $3.6M | -27% | 815k | 4.43 |
|
| Amylyx Pharmaceuticals (AMLX) | 1.3 | $3.4M | NEW | 889k | 3.78 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.2 | $3.0M | -46% | 59k | 51.13 |
|
| Silence Therapeutics Ads (SLN) | 1.1 | $2.7M | -17% | 395k | 6.88 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.0 | $2.6M | NEW | 100k | 25.70 |
|
| Ocular Therapeutix (OCUL) | 0.6 | $1.6M | NEW | 192k | 8.54 |
|
| Mbx Biosciences (MBX) | 0.1 | $332k | NEW | 18k | 18.43 |
|
Past Filings by Saturn V Capital Management
SEC 13F filings are viewable for Saturn V Capital Management going back to 2022
- Saturn V Capital Management 2024 Q4 filed Feb. 14, 2025
- Saturn V Capital Management 2024 Q3 filed Nov. 14, 2024
- Saturn V Capital Management 2024 Q2 filed Aug. 14, 2024
- Saturn V Capital Management 2024 Q1 filed May 15, 2024
- Saturn V Capital Management 2023 Q3 filed Nov. 14, 2023
- Saturn V Capital Management 2023 Q2 filed Aug. 14, 2023
- Saturn V Capital Management 2023 Q1 filed May 15, 2023
- Saturn V Capital Management 2022 Q4 filed Feb. 9, 2023